Drugs / MTX
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07405255 | Jan 2026 → Dec 2027 expected | lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07405255 ↗ |
| Route | Intravenous | “MTX 3.5 mg/m² intravenous on Days 1” NCT07405255 ↗ |